Management of neonatal meningitis, 1984

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neonatal bacterial meningitis continues to cause substantial mortality and morbidity despite the advent of new antimicrobial agents and of modern intensive care facilities. In Dallas, the case-fatality rate for bacterial meningitis in newborn and young infants is 17% (40 of 231 patients). Three pathogens, Group B streptococcus, Escherichia coli and Listeria monocytogenes, accounted for 84% of the causative agents. Although new β-lactam antibiotics have been extensively evaluated in experimental meningitis due to these pathogens, there is limited clinical experience from which to judge efficacy and safety. Currently, conventional therapy with ampicillin and an aminoglycoside should be used as initial empirical therapy for neonatal meningitis. Once the pathogen has been identified and the susceptibilities determined, the most appropriate antibiotic or combination of antibiotics can be selected. Latamoxef (moxalactam) and cefotaxime are highly active agents in vitro against Gram-negative enteric bacilli and may prove useful for therapy of meningitis due to those organisms. Additional experience with these compounds is required before they can be recommended for routine use.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume14
Issue numberSUPPL. B
StatePublished - 1984

Fingerprint

Meningitis
Moxalactam
Bacterial Meningitides
Anti-Bacterial Agents
Lactams
Streptococcus agalactiae
Cefotaxime
Mortality
Listeria monocytogenes
Aminoglycosides
Ampicillin
Critical Care
Anti-Infective Agents
Bacillus
Therapeutics
Newborn Infant
Escherichia coli
Morbidity
Safety

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Management of neonatal meningitis, 1984. / McCracken, G. H.

In: Journal of Antimicrobial Chemotherapy, Vol. 14, No. SUPPL. B, 1984, p. 23-31.

Research output: Contribution to journalArticle

@article{d8b229e885664cacbc6ce7371b3a7604,
title = "Management of neonatal meningitis, 1984",
abstract = "Neonatal bacterial meningitis continues to cause substantial mortality and morbidity despite the advent of new antimicrobial agents and of modern intensive care facilities. In Dallas, the case-fatality rate for bacterial meningitis in newborn and young infants is 17{\%} (40 of 231 patients). Three pathogens, Group B streptococcus, Escherichia coli and Listeria monocytogenes, accounted for 84{\%} of the causative agents. Although new β-lactam antibiotics have been extensively evaluated in experimental meningitis due to these pathogens, there is limited clinical experience from which to judge efficacy and safety. Currently, conventional therapy with ampicillin and an aminoglycoside should be used as initial empirical therapy for neonatal meningitis. Once the pathogen has been identified and the susceptibilities determined, the most appropriate antibiotic or combination of antibiotics can be selected. Latamoxef (moxalactam) and cefotaxime are highly active agents in vitro against Gram-negative enteric bacilli and may prove useful for therapy of meningitis due to those organisms. Additional experience with these compounds is required before they can be recommended for routine use.",
author = "McCracken, {G. H.}",
year = "1984",
language = "English (US)",
volume = "14",
pages = "23--31",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. B",

}

TY - JOUR

T1 - Management of neonatal meningitis, 1984

AU - McCracken, G. H.

PY - 1984

Y1 - 1984

N2 - Neonatal bacterial meningitis continues to cause substantial mortality and morbidity despite the advent of new antimicrobial agents and of modern intensive care facilities. In Dallas, the case-fatality rate for bacterial meningitis in newborn and young infants is 17% (40 of 231 patients). Three pathogens, Group B streptococcus, Escherichia coli and Listeria monocytogenes, accounted for 84% of the causative agents. Although new β-lactam antibiotics have been extensively evaluated in experimental meningitis due to these pathogens, there is limited clinical experience from which to judge efficacy and safety. Currently, conventional therapy with ampicillin and an aminoglycoside should be used as initial empirical therapy for neonatal meningitis. Once the pathogen has been identified and the susceptibilities determined, the most appropriate antibiotic or combination of antibiotics can be selected. Latamoxef (moxalactam) and cefotaxime are highly active agents in vitro against Gram-negative enteric bacilli and may prove useful for therapy of meningitis due to those organisms. Additional experience with these compounds is required before they can be recommended for routine use.

AB - Neonatal bacterial meningitis continues to cause substantial mortality and morbidity despite the advent of new antimicrobial agents and of modern intensive care facilities. In Dallas, the case-fatality rate for bacterial meningitis in newborn and young infants is 17% (40 of 231 patients). Three pathogens, Group B streptococcus, Escherichia coli and Listeria monocytogenes, accounted for 84% of the causative agents. Although new β-lactam antibiotics have been extensively evaluated in experimental meningitis due to these pathogens, there is limited clinical experience from which to judge efficacy and safety. Currently, conventional therapy with ampicillin and an aminoglycoside should be used as initial empirical therapy for neonatal meningitis. Once the pathogen has been identified and the susceptibilities determined, the most appropriate antibiotic or combination of antibiotics can be selected. Latamoxef (moxalactam) and cefotaxime are highly active agents in vitro against Gram-negative enteric bacilli and may prove useful for therapy of meningitis due to those organisms. Additional experience with these compounds is required before they can be recommended for routine use.

UR - http://www.scopus.com/inward/record.url?scp=0021632868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021632868&partnerID=8YFLogxK

M3 - Article

C2 - 6438045

AN - SCOPUS:0021632868

VL - 14

SP - 23

EP - 31

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. B

ER -